Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference14 articles.
1. Subbiah S, Nam A, Garg N, Behal A, Kulkarni P, Salgia R (2020) Small cell lung cancer from traditional to innovative therapeutics: building a comprehensive network to optimize clinical and translational research. J Clin Med 9(8):2433. https://doi.org/10.3390/jcm9082433.PMID:32751469;PMCID:PMC7464169
2. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M (2023) NCCN Guidelines® insights: non-small cell lung cancer, Version 2.2023. J Natl Compr Canc Netw 21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020. (PMID: 37015337)
3. Bergethon K, Shaw AT, Ou S-HI, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863–870
4. Barlesi F, Mazieres J, Merlio J-P. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
5. Gainor JF, Shaw AT (2013) Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31(31):3987–3996